Physician profile
Usha Chandrahasa
NPI 1548254857
$105,503.47
in general payments reported to CMS, 2019-2025
29 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $6,471 · 2021: $12K · 2022: $7,185 · 2023: $30K · 2024: $19K · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $8,742 · Food and Beverage: $3,045 · Education: $49.61 · Consulting Fee: $20.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,287.50 |
| Travel and Lodging | $8,742.43 |
| Food and Beverage | $3,044.88 |
| Education | $49.61 |
| Consulting Fee | $20.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63,854.51 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Shire North American Group INC | $17,780.00 | 2019 | |
| Genentech USA, INC. | $15,274.00 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,280.80 | 2019 | |
| Genzyme Corporation | $1,591.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $895.35 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $617.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $556.12 | 2019-2025 | Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $312.11 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $193.99 | 2022-2025 | Ruconest |
| Adma Biomanufacturing LLC | $193.91 | 2022-2025 | |
| Grifols USA, LLC | $146.24 | 2019 | |
| Pfizer INC. | $118.86 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $110.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.69 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $81.60 | 2024 | Watchman Flx |
| Amgen INC. | $60.51 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $53.02 | 2019-2023 | Yupelri |
| Optinose US, INC. | $50.80 | 2019 | |
| Kaleo, INC. | $44.06 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.38 | 2019 | |
| Octapharma USA, INC. | $26.86 | 2022 | |
| Ionis Pharmaceuticals, INC. | $24.28 | 2025 | Dawnzera |
| Phadia US INC. | $20.71 | 2023 | Immunocap |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Seqirus USA INC | $15.04 | 2019 | |
| Biocryst US Sales Co., LLC | $13.70 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Chandrahasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.